Label Changes for:
Cancidas (caspofungin acetate) for Injection
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
WARNINGS AND PRECAUTIONS
- ...in healthy volunteers and in adult and pediatric patients...In some adult and pediatric patients...
USE IN SPECIFIC POPULATION
- Postmarketing hepatobiliary adverse events have been reported in pediatric patients with serious underlying medical conditions